At the World Vaccine Congress in Lyon 5-8 October, CEO Ole Henrik Brekke will present Vaccibody and its recent results from its influenza program in collaboration with the National Hospital, Norway.
“Previous publications from Vaccibody have been focused on B-cell lymphoma and cancer models. The presentation in Lyon will clearly show that the Vaccibody platform is beneficial also for infectious diseases. This further manifests Vaccibody as versatile vaccine technology “ CEO, Ole Henrik Brekke says in a comment.
Oslo, 29.9.09
Vaccibody AS is a vaccine development company based on a unique technology that enhances the human immune responses compared to other vaccines. The Vaccibody technology allows for the development of therapeutic vaccines. Vaccibody is developing vaccines targeting cancers and infectious diseases.
